IPG Investment Advisors LLC Purchases New Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

IPG Investment Advisors LLC acquired a new position in scPharmaceuticals Inc. (NASDAQ:SCPHFree Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,000 shares of the company’s stock, valued at approximately $75,000.

Several other large investors have also recently made changes to their positions in the stock. AIGH Capital Management LLC grew its stake in scPharmaceuticals by 40.8% during the 4th quarter. AIGH Capital Management LLC now owns 3,106,795 shares of the company’s stock worth $19,480,000 after buying an additional 899,786 shares during the last quarter. Rubric Capital Management LP raised its stake in shares of scPharmaceuticals by 234.3% during the 3rd quarter. Rubric Capital Management LP now owns 2,713,287 shares of the company’s stock worth $19,319,000 after buying an additional 1,901,770 shares during the period. King Luther Capital Management Corp lifted its position in shares of scPharmaceuticals by 48.8% during the 4th quarter. King Luther Capital Management Corp now owns 1,393,525 shares of the company’s stock valued at $8,737,000 after buying an additional 457,150 shares in the last quarter. Worth Venture Partners LLC grew its stake in scPharmaceuticals by 42.9% in the 4th quarter. Worth Venture Partners LLC now owns 771,344 shares of the company’s stock valued at $4,836,000 after acquiring an additional 231,679 shares during the period. Finally, Tejara Capital Ltd purchased a new stake in scPharmaceuticals in the 3rd quarter worth $722,000. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Price Performance

Shares of NASDAQ SCPH traded up $0.07 during midday trading on Tuesday, hitting $3.58. The stock had a trading volume of 79,814 shares, compared to its average volume of 232,821. The company has a quick ratio of 5.44, a current ratio of 6.21 and a debt-to-equity ratio of 1.60. The stock has a 50 day simple moving average of $4.70 and a 200-day simple moving average of $5.33. The company has a market capitalization of $129.06 million, a PE ratio of -2.37 and a beta of 0.09. scPharmaceuticals Inc. has a 1 year low of $3.24 and a 1 year high of $11.75.

scPharmaceuticals (NASDAQ:SCPHGet Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09. The company had revenue of $6.10 million for the quarter, compared to analyst estimates of $6.50 million. scPharmaceuticals had a negative return on equity of 132.39% and a negative net margin of 327.29%. During the same quarter last year, the firm posted ($0.30) EPS. On average, sell-side analysts expect that scPharmaceuticals Inc. will post -1.46 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research report on Wednesday, May 15th.

Check Out Our Latest Research Report on SCPH

scPharmaceuticals Company Profile

(Free Report)

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

Further Reading

Institutional Ownership by Quarter for scPharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.